Arbutus Biopharma Corporation (ABUS)

Arbutus reported its fourth quarter and full-year 2025 financial results, indicating a strong financial position with $91.5 million in cash as of December 31, 2025. The company announced a significant global settlement with Moderna totaling $2.25 billion, including a non-contingent payment of $950 million and a contingent payment of $1.3 billion. A Delaware Court narrowed Moderna's invalidity defenses ahead of the Arbutus LNP Patent Trial. Arbutus reported its third quarter 2025 financial results, with cash at $93.7 million as of September 30, 2025, and highlighted additional analysis of imdusiran clinical data. A favorable claim construction ruling was issued in the Pfizer-BioNTech litigation. The company reported second-quarter 2025 financial results, which included a net income of $2.5 million, partly due to the conclusion of its Greater China partnership with Qilu. Arbutus streamlined its organization to focus on advancing imdusiran and AB-101, which involved ceasing discovery efforts, discontinuing the IM-PROVE III clinical trial, and reducing its workforce.

There is no specific information available to indicate demand seasonality for Arbutus Biopharma Corp.'s products or services. Demand for its products, once commercialized, would likely be driven by disease prevalence and treatment efficacy rather than seasonal patterns.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV) infection. The company operates within the Healthcare sector and the Biotechnology industry, leveraging its expertise in liposomal drug delivery and RNA interference. Its major product candidates include Imdusiran (AB-729), an RNAi therapeutic in Phase 2a clinical trials designed to suppress all HBV antigens, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b clinical trials aimed at reawakening patients' HBV-specific immune response. The company also previously developed and generated royalties from liposomal formulations of off-patent cancer drugs.

Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania, United States. While it is a publicly traded Canadian company, its primary focus for developing novel therapeutics for infectious diseases is in the United States, with North America identified as a key geographic region.

Arbutus Biopharma's brand reputation has been positively impacted by the $2.25 billion global settlement with Moderna regarding patent infringement and favorable rulings in related litigation. The company has also presented positive clinical trial data for its HBV assets, Imdusiran and AB-101, at major conferences, contributing positively to its scientific and development reputation.

Arbutus Biopharma Corporation's ownership structure includes institutional investors, insiders, and public/retail investors. Institutional investors hold a significant portion of the company's stock, with major holders including Morgan Stanley, Whitefort Capital Management, LP, and BlackRock, Inc. Insiders own a smaller percentage of the company's stock. Public companies and individual/retail investors hold the remaining shares.